PFE Pfizer Inc.

39.82
-0.89  -2%
Previous Close 40.71
Open 40.94
Price To Book 3.39
Market Cap 220,368,752,534
Shares 5,534,122,364
Volume 32,391,244
Short Ratio 3.25
Av. Daily Volume 19,650,291
Stock charts supplied by TradingView

NewsSee all news

  1. Pfizer Vaccines Launches Global Centers of Excellence Network to Conduct Real-World Research on Vaccine-Preventable Diseases Affecting Adults

    University of Louisville Named First Center of Excellence Pfizer Inc. (NYSE:PFE) announced today the launch of its Vaccines Division's Centers of Excellence Network, a global program of collaborations with academic

  2. Pfizer's Greenstone and Digital Men's Health Clinic Roman Collaborate to Offer Patients Remote Access to the Only FDA-Approved Authorized Generic Version of Viagra® (sildenafil citrate)

    Agreement provides Roman members with erectile dysfunction treatment backed by Pfizer's quality manufacturing standards and supply chain excellence Greenstone, Upjohn's U.S.-based generics business and a wholly owned

  3. Insilico enters into research collaboration with Pfizer Inc. to explore novel data and artificial intelligence system for potential therapeutic targets

    NEW YORK, Jan. 14, 2020 /PRNewswire/ --  Insilico Medicine is pleased to announce that it has entered into a research collaboration with Pfizer Inc. (NYSE:PFE) to utilize Insilico's machine learning technology and

  4. Biogen to Acquire Novel Clinical Stage Asset with Application in Alzheimer's Disease and Parkinson's Disease from Pfizer Inc.

    PF-05251749 is a CNS-penetrant regulator of circadian rhythm with potential to address behavioral and neurological symptoms across various psychiatric and neurological diseases  Biogen to pay Pfizer $75 million upfront

  5. Axsome Therapeutics Enters into Exclusive License Agreement with Pfizer Inc. for Pfizer's Reboxetine Clinical and Nonclinical Data and for New Phase 3 Esreboxetine Product Candidate

    Agreement accelerates ongoing clinical development of AXS-12 (reboxetine) in narcolepsy Expands Axsome's pipeline with new Phase 3-stage esreboxetine product candidate for fibromyalgia Esreboxetine met primary

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1/2 trial to be initiated in 2018.
Yescarta (Axicabtagene Ciloleucel) and Utomilumab (PF-05082566)
Large B-Cell Lymphoma
Phase 3 data released May 15, 2019 met primary endpoints.
PF-04965842 - abrocitinib
Moderate-to-severe atopic dermatitis (AD)
Approval announced December 13, 2017.
IXIFI
Remicade (infliximab) biosimilar
Phase 3 data released November 28, 2017 - primary endpoint not met.
Avelumab
Gastric cancer
Approval announced October 12, 2017.
LYRICA (pregabalin)
Postherpetic neuralgia (PHN)
Advisory Committee Meeting held November 7, 2017. No votes cast.
Staphylococcus aureus vaccine
Phase 3 data presented at ESMO 2017 - Overall survial HR=0.760 (p=0.09)
XALKORI (crizotinib)
ALK-positive advanced non-small cell lung cancer(NSCLC)
Approval announced September 1, 2017.
Mylotarg (gemtuzumab ozogamicin)
Acute myeloid leukemia (AML)
CRL issued June 22, 2017.
Epoetin alfa biosimilar
FDA approval announced November 2, 2018.
Lorlatinib
ALK+ NSCLC
Approval announced May 9, 2017.
Avelumab
Urothelial Carcinoma
Approval announced August 17, 2017.
Inotuzumab Ozogamicin
Relapsed or Refractory Acute Lymphoblastic Leukemia in Adults
FDA Approval announced December 16, 2019.
XTANDI (ARCHES)
Metastatic hormone sensitive prostate cancer
Phase 3 trial terminated - noted May 17, 2017.
XTANDI (ENDEAR)
Triple negative breast cancer
Phase 3 data due 2H 2020.
XTANDI (EMBARK)
Non-metastatic high risk hormone-sensitive prostate cancer
FDA approval announced July 13, 2018.
XTANDI (PROSPER)
Non-metastatic high risk hormone-sensitive prostate cancer
Approval announced May 30, 2018.
Xeljanz
Ulcerative colitis
Approval announced December 14, 2017.
Xeljanz
Psoriatic arthritis
FDA Approval announced October 16, 2018.
Talazoparib
BRCA-mutated breast cancer
Approval announced 16 November, 2017.
Sutent (Sunitinib)
Renal cell carcinoma (RCC)
Phase 3 trial met primary endpoint - December 2016.
LYRICA (pregabalin)
Pediatric Epilepsy
Approval announced December 20, 2017.
Ertugliflozin
Type 2 diabetes
Approval announced December 19, 2017.
BOSULIF (BOSUTINIB)
First-Line Treatment of Philadelphia Chromosome Positive Chronic Myeloid Leukemia
Priority review announced November 29, 2016. Approval announced March 23, 2017.
Avelumab
Metastatic Merkel cell carcinoma
sNDA acceptance announced December 21, 2016. Approval announced March 31, 2017.
IBRANCE (palbociclib)
HR+, HER2- Metastatic Breast Cancer
Phase 3 data released February 19, 2019. 10mg dose met primary endpoint. 5mg dose did not meet endpoint.
Tanezumab
Chronic low back pain
Phase 3 data from second trial released January 29, 2019 - co-primary endpoints met. Data from trial April 18, 2019 met 2/3 primary endpoints in 5mg arm but failed to meet endpoints in 2.5mg arm. Regulatory filing due 4Q 2019 or early 2020.
Tanezumab
Osteoarthritis
Phase 3 data due 1H 2020.
Tanezumab
Cancer pain
Approval announced June 27, 2018.
Binimetinib - COLUMBUS
BRAF mutant melanoma cancer
Phase 3 trial enrolling - November 2018.
ARRY 797
LMNA A/C-related dilated cardiomyopathy (DCM)
Phase 3 data failed to meet endpoints - August 2, 2019.
GMI-1070 (rivipansel)
Vaso-occlusive crisis of sickle cell disease
Approved Sept 10 2014
XTANDI
Cancer - mCRPC who have not received chemotherapy
PDUFA date under priority review for sNDA April 2020.
Encorafenib and cetuximab - BEACON CRC
BRAF-Mutant Colorectal Cancer
FDA Approval announced May 6, 2019.
Tafamidis (tafamidis free acid form)
Transthyretin amyloid cardiomyopathy (ATTR-CM)
FDA Approval announced September 27, 2018.
Dacomitinib
Non-small cell lung cancer (NSCLC)
Complete Response Letter issued December 21, 2019.
Dolutegravir + rilpivirine
HIV
Phase 3 trial discontinued due to futility.
INLYTA (axitinib)
Recurrent renal cell carcinoma (RCC)
Phase 1b data June 28, 2019 noted safety concerns. Phase 3 trial to commence 1H 2020.
PF-06939926
Duchenne muscular dystrophy (DMD)
Phase 3 overall survival secondary endpoint not met - June 25, 2018. PFS primary endpoint met (announced previously).
IBRANCE - PALOMA-3
Breast cancer
Phase 3 presentation at ASCO June 2018.
IBRANCE (palbociclib)
Head and neck squamous cell carcinoma
FDA approval announced November 21, 2018.
Glasdegib
Acute myeloid leukemia (AML)
Phase 3 lead-in trial initiation announced July 16, 2018.
FIX Replacement therapy
Hemophilia B
Phase 2 development terminated due to lack of efficacy.
Domagrozumab
Duchenne muscular dystrophy (DMD)
FDA Approval announced May 14, 2019.
BAVENCIO (avelumab) and INLYTA (axitinib)
Renal cell carcinoma (RCC)
FDA approval announced April 22, 2019.
KEYTRUDA and Inlyta - KEYNOTE-426
Renal cell carcinoma
FDA Approval March 11, 2019.
PF-05280014 TRAZIMERA
Herceptin biosimilar
Phase 3 trial to be terminated due to lack of efficacy.
Avelumab - JAVELIN Ovarian 100
Ovarian cancer
Phase 3 data due 2H 2021.
PF-06651600 - JAK3
Alopecia areata
FDA approval announced May 6, 2019.
Tafamidis
Transthyretin amyloid cardiomyopathy (ATTR-CM)
FDA approval of sNDA announced April 4, 2019.
IBRANCE (palbociclib)
HR+/HER2- advanced breast cancer in men
Phase 3 data due 2H 2020.
IBRANCE (palbociclib) - PENELOPE
Early stage breast cancer
Phase 3 data due 2H 2020.
IBRANCE (palbociclib) - PALLAS
Early stage breast cancer
Phase 3 data due 1H 2020.
Avelumab - Bavencio
Gastric cancer
Phase 3 data due 1H 2020.
Avelumab - Bavencio
Urothelial Cancer
Phase 3 data due 2H 2020.
PF-06425090
C. difficile Infection
Phase 3 data released May 24, 2019 did not meet primary endpoint.
LYRICA (pregabalin)
Primary generalized tonic-clonic (PGTC) seizures - epilepsy
FDA Approval announced June 28, 2019.
PF-06439535
Biosimilar bevacizumab
Phase 3 trial did not meet primary endpoint - June 28, 2019.
Sildenafil and inhaled nitric oxide (iNO)
Persistent Pulmonary Hypertension (PPHN)
FDA approval announced July 23, 2019.
Ruxience (Biosimilar to Rituxan)
CD20-positive, low tumor burden, follicular lymphoma.
Phase 3 trial met primary and secondary endpoints - September 27, 2019.
Abrocitinib
Atopic Dermatitis
Phase 3 trial to commence in 2020.
Marstacimab (PF-06741086)
Hemophilia A or B
Phase 3 endpoint not met - November 8, 2019.
Avelumab - JAVELIN Gastric 100
Gastric cancer
Phase 3 trial met primary endpoint.
Tofacitinib
Juvenile idiopathic arthritis (JIA)
FDA Approval announced November 18, 2019.
ABRILADA (adalimumab-afzb)
Bosimilar to Humira (adalimumab)
NDA filing announced December 5, 2019.
Fostemsavir
HIV
Phase 3 trial met overall survival primary endpoint - January 6, 2020.
Bavencio (Avelumab) - JAVELIN Bladder 100
Bladder cancer

Latest News

  1. Pfizer Vaccines Launches Global Centers of Excellence Network to Conduct Real-World Research on Vaccine-Preventable Diseases Affecting Adults

    University of Louisville Named First Center of Excellence Pfizer Inc. (NYSE:PFE) announced today the launch of its Vaccines Division's Centers of Excellence Network, a global program of collaborations with academic

  2. Pfizer's Greenstone and Digital Men's Health Clinic Roman Collaborate to Offer Patients Remote Access to the Only FDA-Approved Authorized Generic Version of Viagra® (sildenafil citrate)

    Agreement provides Roman members with erectile dysfunction treatment backed by Pfizer's quality manufacturing standards and supply chain excellence Greenstone, Upjohn's U.S.-based generics business and a wholly owned

  3. Insilico enters into research collaboration with Pfizer Inc. to explore novel data and artificial intelligence system for potential therapeutic targets

    NEW YORK, Jan. 14, 2020 /PRNewswire/ --  Insilico Medicine is pleased to announce that it has entered into a research collaboration with Pfizer Inc. (NYSE:PFE) to utilize Insilico's machine learning technology and

  4. Biogen to Acquire Novel Clinical Stage Asset with Application in Alzheimer's Disease and Parkinson's Disease from Pfizer Inc.

    PF-05251749 is a CNS-penetrant regulator of circadian rhythm with potential to address behavioral and neurological symptoms across various psychiatric and neurological diseases  Biogen to pay Pfizer $75 million upfront

  5. Axsome Therapeutics Enters into Exclusive License Agreement with Pfizer Inc. for Pfizer's Reboxetine Clinical and Nonclinical Data and for New Phase 3 Esreboxetine Product Candidate

    Agreement accelerates ongoing clinical development of AXS-12 (reboxetine) in narcolepsy Expands Axsome's pipeline with new Phase 3-stage esreboxetine product candidate for fibromyalgia Esreboxetine met primary

  6. BAVENCIO Significantly Improved Overall Survival in Patients with Locally Advanced or Metastatic Urothelial Carcinoma

    EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada, and Pfizer Inc. (NYSE:PFE) today announced the Phase III JAVELIN Bladder 100 study met its primary endpoint of overall

  7. ViiV Healthcare submits regulatory application to the European Medicines Agency for fostemsavir, an investigational, first-in-class attachment inhibitor for the treatment of HIV in adults with few treatment options available

    ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today announced the submission of a marketing authorisation application (MAA) to the

  8. eFFECTOR Enters Into Agreement with Pfizer Inc. to Develop Novel First-in-Class Inhibitors of eIF4E to Treat Multiple Cancer Types

    SAN DIEGO, Jan. 09, 2020 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulators (STRs) for the treatment of cancer, and Pfizer Inc. (NYSE:PFE) today announced

  9. Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

    Pfizer Inc. (NYSE:PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the 38th Annual J.P. Morgan Healthcare Conference on

  10. BAVENCIO Significantly Improved Overall Survival in Patients With Locally Advanced or Metastatic Urothelial Carcinoma

    ROCKLAND, Mass. and NEW YORK, Jan. 6, 2020 /PRNewswire/ -- EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada, and Pfizer Inc. (NYSE:PFE) today announced the Phase III

  11. Theravance Biopharma and Pfizer Inc. Enter Global License Agreement for Skin-Targeted, Locally-Acting Pan-Janus Kinase (JAK) Inhibitor Program

    DUBLIN and NEW YORK, Dec. 23, 2019 /PRNewswire/ -- Theravance Biopharma Ireland Limited, a subsidiary of Theravance Biopharma, Inc. (NASDAQ:TBPH) ("Theravance Biopharma") and Pfizer Inc. (NYSE:PFE)

  12. BioInvent Announces Selection of Second Target and Extension of the Research Collaboration and License Agreement With Pfizer Inc.

    LUND, Sweden, Dec. 23, 2019 /PRNewswire/ -- BioInvent International AB ("BioInvent" or the "Company") (OMXS: BINV) today announces that Pfizer Inc. ("Pfizer") (NYSE:PFE) has selected the second

  13. ViiV Healthcare receives complete response letter from US FDA for use of investigational cabotegravir and rilpivirine long-acting regimen in the treatment of HIV

    ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, received a complete response letter (CRL) from the US Food and Drug Administration (FDA)

  14. Pfizer Declares First-Quarter 2020 Dividend and Announces Upcoming Investor Day to Highlight Strength of Innovative R&D Pipeline

    Pfizer Inc. (NYSE:PFE) announced today that its board of directors declared a 38-cent per share first-quarter 2020 dividend on the company's common stock, payable March 6, 2020 to holders of the Common Stock of

  15. U.S. FDA Accepts and Grants Priority Review to sNDA for BRAFTOVI® (encorafenib) in Combination with ERBITUX® (cetuximab) (BRAFTOVI Doublet) for the Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer After Prior Therapy

    Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted priority review to the Company's supplemental New Drug Application (sNDA) for BRAFTOVI® (encorafenib) in

  16. Pfizer and Mylan Announce Two Future Viatris Board Members

    Ian Read and James Kilts offer strong experience to support long-term value creation Pfizer Inc. (NYSE:PFE) and Mylan N.V. (NASDAQ:MYL) today announced that Ian Read and James Kilts will join the Viatris board of

  17. Pfizer and Mylan Announce Two Future Viatris Board Members

    NEW YORK, Dec. 18, 2019 /PRNewswire/ -- Pfizer Inc. (NYSE:PFE) and Mylan N.V. (NASDAQ:MYL) today announced that Ian Read and James Kilts will join the Viatris board of directors upon completion of the planned combination

  18. Pfizer Invites Public to View and Listen to Webcast of January 28 Conference Call with Analysts

    Pfizer Inc. (NYSE:PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EST on Tuesday, January 28, 2020. The purpose of the call is to

  19. Triplet Therapeutics Launches with $59 Million in Financing to Further its Development of Transformative Treatments for Triplet Repeat Disorders

    - Triplet was formed by Atlas Venture and CEO Nessan Bermingham to create a new treatment paradigm for repeat expansion disorders - The company's approach targets the common pathway involved in triplet repeat

  20. XTANDI® (enzalutamide) Approved by U.S. FDA for the Treatment of Metastatic Castration-Sensitive Prostate Cancer

    NEW YORK and TOKYO, Dec. 16, 2019 /PRNewswire/ -- Pfizer Inc. (NYSE:PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") announced today that the U.S. Food and Drug

  21. XTANDI® (enzalutamide) Approved by U.S. FDA for the Treatment of Metastatic Castration-Sensitive Prostate Cancer

    XTANDI is Now FDA-Approved for the Treatment of Metastatic Castration-Sensitive Prostate Cancer in Addition to Non-Metastatic and Metastatic Castration-Resistant Prostate Cancer Pfizer Inc. (NYSE:PFE) and Astellas

  22. Pfizer Declares First-Quarter 2020 Dividend and Announces Upcoming Investor Day to Highlight Strength of Innovative R&D Pipeline

    Board of Directors approves first-quarter 2020 cash dividend of $0.38 per share Investor Day scheduled for March 31, 2020 to showcase mid-to-late-stage R&D pipeline progress and commercial momentum across

  23. Pfizer Receives Positive CHMP Opinion for VYNDAQEL® for Use in Patients with Transthyretin Amyloid Cardiomyopathy, a Rare and Fatal Disease

    —If approved by the European Commission (EC), VYNDAQEL® will be the first pharmacologic therapy in the EU for patients with transthyretin amyloid cardiomyopathy— Pfizer Inc. (NYSE:PFE) announced today that the

  24. FDA Approves XELJANZ® XR (tofacitinib) Extended-Release Tablets for the Treatment of Ulcerative Colitis

    XELJANZ XR provides adult patients living with moderately to severely active UC the first and only once-daily JAK inhibitor for managing their disease Pfizer Inc. (NYSE:PFE) announced today that the U.S. Food and Drug

  25. ImmunOs Therapeutics AG Raises CHF 15M in Series A Financing, Co-led by Pfizer Ventures and BioMedPartners, to Advance a Novel Immunotherapy Agent For Cancer Into Human Trials

    ImmunOs Therapeutics AG, a Swiss bio-technology company and leading developer of a next generation innate immunity focused immunotherapy platform for cancer, announced today the closing of a Series A financing of CHF 15

  26. Sangamo and Pfizer Announce Updated Phase 1/2 Results Showing Sustained Increased Factor VIII Activity Through 44 Weeks Following SB-525 Gene Therapy Treatment

    - The first two patients treated with the 3e13 vg/kg dose achieved stable Factor VIII (FVIII) levels demonstrating durability in the normal range through 44 and 37 weeks, respectively - All five patients in the 3e13

  27. ViiV Healthcare submits New Drug Application to the FDA for fostemsavir, an investigational, first-in-class attachment inhibitor for the treatment of HIV in adults with few treatment options available

    ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today completed submission of a New Drug Application (NDA) to the US Food and Drug

  28. Centogene reporting its financial results for the three months and nine months ended September 30, 2019

    CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec. 05, 2019 (GLOBE NEWSWIRE) -- CENTOGENE N.V. (NASDAQ:CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data

  29. ImCheck Raises $53 Million Series B to Advance Clinical Pipeline of Novel Gamma Delta T-Cell-Focused Antibodies for Cancer and Autoimmune Diseases

    -- Bpifrance and Pfizer Ventures co-led international investor syndicate -- Marseille, France, December 04, 2019, 6:45 AM CET – ImCheck Therapeutics, a biotech company developing a first-in-class antibody to activate

  30. Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

    Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with Mikael Dolsten, Chief Scientific Officer and President, Worldwide Research, Development and Medical, and Michael Vincent,

  31. Astellas Announces the Approval of XTANDI® (enzalutamide) by the China National Medical Products Administration (NMPA)

    TOKYO, Nov. 25, 2019 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced that the China National Medical Products Administration (NMPA) approved

  32. ViiV Healthcare announces exclusive licensing agreement with the National Institutes of Health for investigational "bNAb" with potential for long-acting HIV treatment and prevention

    ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today announced that the company will be developing the investigational broadly

  33. Akcea and Ionis Announce Closing of Licensing Agreement with Pfizer Inc. for Investigative Antisense Therapy AKCEA-ANGPTL3-L(Rx)

    BOSTON and CARSLBAD, Calif., Nov. 19, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ:IONS), today

  34. FDA Approves Pfizer's Biosimilar, ABRILADA™ (adalimumab-afzb) for Multiple Inflammatory Conditions

    Pfizer Inc. (NYSE:PFE) today announced the United States (U.S.) Food and Drug Administration (FDA) has approved ABRILADA™ (adalimumab-afzb), as a biosimilar to Humira® (adalimumab),1 for the treatment of certain

  35. Bristol-Myers Squibb and Pfizer Announce Randomized, Controlled Trial to Evaluate the Effect of Atrial Fibrillation Screening on Health Outcomes in Older Individuals

    The Bristol-Myers Squibb-Pfizer Alliance today announced the initiation of a new randomized, controlled study, GUARD-AF (ReducinG stroke by screening for UndiAgnosed atRial fibrillation in elderly inDividuals). The

  36. CENTOGENE Signs Data Access and Collaboration Agreement with Pfizer Inc.

    CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Nov. 13, 2019 (GLOBE NEWSWIRE) -- CENTOGENE (NASDAQ:CNTG),  a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data

  37. Mylan and Pfizer Announce Viatris as the New Company Name in the Planned Mylan-Upjohn Combination

    Mylan N.V. (NASDAQ:MYL) and Pfizer Inc. (NYSE:PFE) today announced that the name of the new company to be formed by the planned combination of Mylan and Upjohn, a division of Pfizer, will be Viatris (pronounced

  38. Mylan and Pfizer Announce Viatris as the New Company Name in the Planned Mylan-Upjohn Combination

    HERTFORDSHIRE, England, PITTSBURGH and NEW YORK, Nov. 12, 2019 /PRNewswire/ -- Mylan N.V. (NASDAQ:MYL) and Pfizer Inc. (NYSE:PFE) today announced that the name of the new company to be formed by the planned combination

  39. Pfizer Announces Results of Phase 3 Study for XELJANZ® (tofacitinib) in Juvenile Idiopathic Arthritis Ahead of Presentation at 2019 American College of Rheumatology/Association of Rheumatology Professionals Annual Meeting

    Pfizer Inc. (NYSE:PFE) announced today that positive results from a Phase 3 investigational study of tofacitinib in children and adolescents aged two to less than 18 with juvenile idiopathic arthritis (JIA) will be

  40. Merck and Pfizer Provide Update on Phase III JAVELIN Gastric 100 Trial

    Not intended for US, Canada and UK-based media  DARMSTADT, Germany, and NEW YORK, Nov. 8, 2019 /CNW/ -- Merck and Pfizer Inc. (NYSE:PFE) today announced topline results of the Phase III JAVELIN Gastric 100 study

  41. EMD Serono and Pfizer Provide Update on Phase III JAVELIN Gastric 100 Trial

    ROCKLAND, Mass. and NEW YORK, Nov. 8, 2019 /PRNewswire/ -- EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada, and Pfizer Inc. (NYSE:PFE) today announced topline results of

  42. PFIZER REPORTS THIRD-QUARTER 2019 RESULTS

    Third-Quarter 2019 Revenues of $12.7 Billion, Reflecting 3% Operational Decline; Excluding the Impact from Consumer Healthcare(1), Third-Quarter 2019 Revenues were Flat Operationally – 9% Operational Growth from

  43. ImaginAb signs multi-party collaboration agreement with three global pharmaceutical companies to help further develop company's CD8 ImmunoPET technology

    LOS ANGELES, Oct. 14, 2019 /PRNewswire/ -- ImaginAb, Inc., a leading clinical-stage immuno-oncology imaging company, today announced the signing of a multi-party collaboration agreement with AstraZeneca (NYSE:AZN),

  44. Pfizer Presents Positive Phase 3 Data at the 28th Congress of the European Academy of Dermatology and Venereology for Abrocitinib in Moderate to Severe Atopic Dermatitis

    –Abrocitinib met all co-primary and secondary endpoints in JADE MONO-1 study– –Findings follow recent positive top-line results for second abrocitinib Phase 3 pivotal study, JADE MONO-2– Pfizer Inc. (NYSE:PFE)

  45. Akcea and Pfizer Inc. Announce Licensing Agreement for investigative antisense therapy AKCEA-ANGPTL3-LRx

    Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) and Pfizer Inc. (NYSE:PFE), today announced that the companies have entered into a worldwide exclusive

  46. Akcea and Pfizer Inc. Announce Licensing Agreement for investigative antisense therapy AKCEA-ANGPTL3-L(Rx)

    BOSTON and NEW YORK, Oct. 07, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) and Pfizer Inc. (NYSE:PFE), today announced that

  47. Checkmate Pharmaceuticals Announces Dosing of First Patient in a Phase 1b/2 Study in Squamous Cell Carcinoma of the Head and Neck with Lead Investigational Candidate CMP-001

    CMP-001, a TLR9 Agonist, to be Evaluated in Combination with BAVENCIO®; with or without Utomilumab, a 4-1BB Agonist, and PF-04518600, an OX40 Agonist Checkmate Pharmaceuticals Inc., a clinical stage biopharmaceutical

  48. Transgene Reports First Promising Efficacy Results with TG4001 in Combination with Avelumab in HPV-Positive Cancer at ESMO 2019

    Three of six patients showed durable responses (patients treated with the recommended Phase 2 dose)1 Combination therapy results in changes in tumor microenvironment shifting immune status from "cold" to "hot"

  49. Companies Seek an Innovative Solution to the Growing Cancer Rates

    NEW YORK, Sept. 30, 2019 /PRNewswire/ -- Cancer is among the leading causes of death in the world as countries are burdened by a lack of access to adequate healthcare. In 2018, the World Cancer Research Fund (WCRF)

  50. Pfizer Presents Interim Analysis Results from Phase 3 BEACON CRC Trial of BRAFTOVI® (Encorafenib), MEKTOVI® (Binimetinib) and Cetuximab for the Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer

    - Results to be presented during a late-breaking oral session at the 2019 ESMO Congress and simultaneously published in The New England Journal of Medicine – - As previously announced, BRAFTOVI combinations showed

  51. Pfizer and Flatiron Health Announce Expanded Strategic Collaboration to Unlock Power of Real-World Evidence in Oncology

    Pfizer Inc. (NYSE:PFE) and Flatiron Health today announced an expanded strategic collaboration to further integrate and increase the use of real-world data in Pfizer's development of innovative targeted cancer

  52. Pfizer Inc. Awards "Golden Tickets" to Neutrolis and Mediar Therapeutics

    Winners of the Pfizer Golden Ticket Program announced last night during a panel discussion and networking event at Pfizer's Cambridge, MA R&D site Pfizer Inc. and LabCentral announced that Pfizer has selected

  53. Ian Read to Retire as Executive Chairman of Pfizer's Board of Directors; Chief Executive Officer Dr. Albert Bourla Named Chairman

    Following its regularly scheduled meeting, the Board of Directors of Pfizer Inc. (NYSE:PFE) today announced that Executive Chairman of the Board Ian C. Read has chosen to retire on December 31, 2019, and that it has

  54. Pfizer Announces Positive Top-Line Results from Second Pivotal Phase 3 Study of Investigational Oral JAK1 Candidate, Abrocitinib, in Patients Aged 12 and Older with Moderate to Severe Atopic Dermatitis

    –Study achieves all co-primary and key secondary endpoints– –Safety results show both doses of abrocitinib consistent with prior clinical trial experiences– Pfizer Inc. (NYSE:PFE) announced today positive top-line

  55. New Data for BAVENCIO® (avelumab) for Advanced Cancers to Be Presented at ESMO 2019

    Analyses from the Phase III JAVELIN Renal 101 study support efficacy of BAVENCIO plus axitinib across multiple subgroups of patients with advanced renal cell carcinoma (RCC) Abstracts highlight data on BAVENCIO as a

  56. Pfizer and Flatiron Health Announce Expanded Strategic Collaboration to Unlock Power of Real-World Evidence in Oncology

    Pfizer Inc. (NYSE:PFE) and Flatiron Health today announced an expanded strategic collaboration to further integrate and increase the use of real-world data in Pfizer's development of innovative targeted cancer

  57. Pfizer Declares Fourth-Quarter 2019 Dividend

    Board of Directors approves quarterly cash dividend to $0.36 per share The Board of Directors of Pfizer Inc. today declared a 36-cent fourth-quarter 2019 dividend on the company's common stock, payable December 2,

  58. CHMP Adopts Positive Opinion for BAVENCIO® (avelumab) Plus Axitinib for First-Line Treatment of Patients with Advanced Renal Cell Carcinoma

    ROCKLAND, MA and NEW YORK, US, September 20, 2019 /PRNewswire/ -- EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada, and Pfizer Inc. (NYSE:PFE) today announced that the

  59. Pfizer Presents Scientific Advancements in Cancer Care at the ESMO Congress 2019 Highlighting Expanded Portfolio

    Presentations of interest include a late-breaking abstract on expanded Phase 3 data in BRAF-mutant metastatic colorectal cancer Pfizer Inc. (NYSE:PFE) is presenting data across its industry-leading oncology portfolio,

  60. Biotech Companies Endeavor to Address Global Health Issues

    NEW YORK, Sept. 18, 2019 /PRNewswire/ -- The global burden of diseases continues to grow each year, despite ongoing medical advancements. The Institute for Health Metrics and Evaluation (IHME) highlighted in a report

  61. Pfizer Invites Public to View and Listen to Webcast of October 29 Conference Call With Analysts

    Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, October 29, 2019. The purpose of the call is to provide an

  62. Pfizer Announces Positive Preliminary Results from a Proof-of-Concept Phase 2 Study (B7471003) of its 20-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Disease and Otitis Media in Healthy Infants

    Pfizer Inc. (NYSE:PFE) announced positive preliminary results following administration of three doses in a four-dose series for a Proof-of-Concept Phase 2 study (B7471003) to assess safety and immunogenicity of its

  63. Pfizer Announces Positive Preliminary Results from a Proof-of-Concept Phase 2 Study (B7471003) of its 20-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Disease and Otitis Media in Healthy Infants

    Additionally, Pfizer Has Completed Enrollment of its Phase 3 Studies (NCT03828617, NCT03835975 and NCT03760146) for its 20-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of

  64. Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

    Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with Frank D'Amelio, Chief Financial Officer and Executive Vice President, Global Supply and Business Operations, at the Morgan

  65. ViiV Healthcare reports positive phase III study results of investigational, long-acting, injectable HIV-treatment regimen administered every two months

    ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today announced positive headline results from its global phase III ATLAS-2M study of the

  66. U.S. FDA Grants XTANDI® (enzalutamide) Application Priority Review for the Treatment of Men with Metastatic Hormone-Sensitive Prostate Cancer

    TOKYO & Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and Pfizer Inc. (NYSE:PFE) announced that the U.S. Food and Drug Administration (FDA) has accepted for review

  67. ViiV Healthcare Reports Positive Phase III Study Results of Investigational, Long-acting, Injectable HIV-Treatment Regimen Administered Every Two Months

    ATLAS-2M study met its primary endpoint, showing similar efficacy of cabotegravir and rilpivirine administered every eight weeks compared to four-week administration ViiV Healthcare, the global specialist HIV company